Clinical Trial Update: A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model [Phase 3]

View source ↗

Summary

A multicenter Phase III trial protocol evaluating adaptive neoadjuvant therapy (de-escalation and escalation) for HER2-positive breast cancer guided by a multi-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy | Phase 3 | Status: NOT_YET_RECRUITING